BioNxt Solutions 更新了 MS 的舌下含服克拉屈滨计划，计划在 2025 年进行人体研究。 BioNxt Solutions updates sublingual Cladribine program for MS, plans human study in 2025.

BioNxt Solutions Inc.更新了其用于帮助吞咽困难病人的多发性硬化症(MS)亚语言克拉德里宾方案。 BioNxt Solutions Inc. updated its sublingual Cladribine program for Multiple Sclerosis (MS), designed to assist patients with swallowing difficulties. 据报动物研究取得了积极结果,并计划在2025年初进行人类生物等值比较研究。 Positive results from animal studies were reported, and a human comparative bioequivalence study is planned for early 2025. 该公司获得了针对自身免疫性神经退行性疾病的抗癌药物的下舌传递的有利专利审查,并旨在扩大其专利组合. The company received a favorable patent examination for sublingual delivery of anticancer drugs targeting autoimmune neurodegenerative diseases and aims to expand its patent portfolio. BioNxt还正在开发一个Myasthenia Gravis的运载系统。 BioNxt is also developing a delivery system for Myasthenia Gravis.